Literature DB >> 7956734

Theoretical kinetics of sequential metabolism in vitro. Study of the formation of 16 alpha-hydroxyandrostenedione from testosterone by purified rat P450 2C11.

K Sugiyama1, K Nagata, J R Gillette, J F Darbyshire.   

Abstract

P450 2C11 from rat liver is known to metabolize testosterone to 2 alpha-, 16 alpha-, and 6 beta-hydroxytestosterone, and to androstenedione and 16 alpha-hydroxyandrostenedione. Because Waxman (J. Biol. Chem. 259, 15481-15490) has reported that the enzyme converts androstenedione to 16 alpha-hydroxyandrostenedione, it seemed likely that the metabolite was formed from testosterone by way of androstenedione. Indeed, we have found that P450 2C11 does not convert 16 alpha-hydroxytestosterone to 16 alpha-hydroxyandrostenedione to any significant extent and, therefore, that the metabolite is formed from testosterone almost solely by way of androstenedione. To determine whether some of the 16 alpha-hydroxyandrostenedione might be formed directly from the androstenedione-enzyme complex, we developed an approach by which it is possible to calculate the amount of the androstenedione, released into the medium, relative to the amount of the androstenedione-enzyme complex that is converted directly to 16 alpha-hydroxyandrostenedione under initial conditions when the concentration of released androstenedione will be negligible. The approach uses two factors: factor A is the androstenedione/(androstenedione + 16 alpha-hydroxyandrostenedione) present at the end of the incubation, and factor B corrects for the amount of released androstenedione that recombines with the enzyme and is converted to 16 alpha-hydroxyandrostenedione. Although the values of both factors A and B will vary with the concentrations of testosterone and preformed androstenedione present in the incubation mixtures and with the duration of incubation, the value of A*B will be independent of these parameters.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7956734

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

1.  Allosteric activation of cytochrome P450 3A4 by α-naphthoflavone: branch point regulation revealed by isotope dilution analysis.

Authors:  Caleb M Woods; Cristina Fernandez; Kent L Kunze; William M Atkins
Journal:  Biochemistry       Date:  2011-10-28       Impact factor: 3.162

2.  Multienzyme Kinetics and Sequential Metabolism.

Authors:  Larry C Wienkers; Brooke M Rock
Journal:  Methods Mol Biol       Date:  2021

Review 3.  Multi-step oxidations catalyzed by cytochrome P450 enzymes: Processive vs. distributive kinetics and the issue of carbonyl oxidation in chemical mechanisms.

Authors:  F Peter Guengerich; Christal D Sohl; Goutam Chowdhury
Journal:  Arch Biochem Biophys       Date:  2010-09-04       Impact factor: 4.013

4.  Oxidation of N-Nitrosoalkylamines by human cytochrome P450 2A6: sequential oxidation to aldehydes and carboxylic acids and analysis of reaction steps.

Authors:  Goutam Chowdhury; M Wade Calcutt; F Peter Guengerich
Journal:  J Biol Chem       Date:  2010-01-08       Impact factor: 5.157

Review 5.  Time-dependent enzyme inactivation: Numerical analyses of in vitro data and prediction of drug-drug interactions.

Authors:  Jaydeep Yadav; Erickson Paragas; Ken Korzekwa; Swati Nagar
Journal:  Pharmacol Ther       Date:  2019-12-11       Impact factor: 12.310

6.  Characterization of a second secologanin synthase isoform producing both secologanin and secoxyloganin allows enhanced de novo assembly of a Catharanthus roseus transcriptome.

Authors:  Thomas Dugé de Bernonville; Emilien Foureau; Claire Parage; Arnaud Lanoue; Marc Clastre; Monica Arias Londono; Audrey Oudin; Benjamin Houillé; Nicolas Papon; Sébastien Besseau; Gaëlle Glévarec; Lucia Atehortùa; Nathalie Giglioli-Guivarc'h; Benoit St-Pierre; Vincenzo De Luca; Sarah E O'Connor; Vincent Courdavault
Journal:  BMC Genomics       Date:  2015-08-19       Impact factor: 4.547

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.